Reboxetine

CHEMBL14370 Phase 4 Aprobado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

313.4 g/mol

LogP

3.0

Phase

4

A selective norepinephrine reuptake inhibitor used outside the United States to treat major depressive disorder by increasing norepinephrine levels in the brain. It differs from most antidepressants by having minimal effect on serotonin reuptake.

Peso molecular

313,4000 g/mol

LogP

3,00

TPSA

39,70 Å²

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Dolor crónico Esquizofrenia Ictus Manejo del dolor Obesidad Trastorno de ansiedad generalizada Trastorno depresivo mayor

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estructura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CCOc1ccccc1OC(c1ccccc1)C1CNCCO1

InChI

InChI=1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3

Molecular Formula

C19H23NO3

HBD / HBA

1 / 4

Enlaces Rotables

6

Átomos Pesados

23

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

A selective norepinephrine reuptake inhibitor used outside the United States to treat major depressive disorder by increasing norepinephrine levels in the brain. It differs from most antidepressants by having minimal effect on serotonin reuptake.

Yes, Reboxetine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL14370. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 127151. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

¿Busca información accesible para el paciente?

Reboxetine en PillFYI

Estructura

Datos Rápidos

Fórmula: C19H23NO3

Enlaces externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.